Literature DB >> 27840148

Primary Angioplasty in Patients Older Than 75 Years. Profile of Patients and Procedures, Outcomes, and Predictors of Prognosis in the ESTROFA IM+75 Registry.

José M de la Torre Hernández1, Salvatore Brugaletta2, Joan A Gómez Hospital3, José A Baz4, Armando Pérez de Prado5, Ramón López Palop6, Belén Cid7, Tamara García Camarero8, Alejandro Diego9, Federico Gimeno de Carlos10, José A Fernández Díaz11, Juan Sanchis12, Fernando Alfonso13, Roberto Blanco14, Javier Botas15, Javier Navarro Cuartero16, José Moreu17, Francisco Bosa18, José M Vegas Valle19, Jaime Elízaga20, Antonio L Arrebola21, José R Ruiz Arroyo22, Felipe Hernández-Hernández23, Neus Salvatella24, Marta Monteagudo25, Alfredo Gómez Jaume26, Xavier Carrillo27, Roberto Martín Reyes28, Fernando Lozano29, José R Rumoroso30, Leire Andraka31, Antonio J Domínguez32.   

Abstract

INTRODUCTION AND
OBJECTIVES: The proportion of elderly patients undergoing primary angioplasty is growing. The present study describes the clinical profile, procedural characteristics, outcomes, and predictors of outcome.
METHODS: A 31-center registry of consecutive patients older than 75 years treated with primary angioplasty. Clinical and procedural data were collected, and the patients underwent clinical follow-up.
RESULTS: The study included 3576 patients (39.3% women, 48.5% with renal failure, 11.5% in Killip III or IV, and 29.8% with>6hours of chest pain). Multivessel disease was present in 55.4% and nonculprit lesions were additionally treated in 24.8%. Radial access was used in 56.4%, bivalirudin in 11.8%, thromboaspiration in 55.9%, and drug-eluting stents in 26.6%. The 1-month and 2-year incidences of cardiovascular death were 10.1% and 14.7%, respectively. The 2-year rates of definite or probable thrombosis, repeat revascularization, and BARC bleeding>2 were 3.1%, 2.3%, and 4.2%, respectively. Predictive factors were diabetes mellitus, renal failure, atrial fibrillation, delay to reperfusion>6hours, ejection fraction<45%, Killip class III-IV, radial access, bivalirudin, drug-eluting stents, final TIMI flow of III, and incomplete revascularization at discharge.
CONCLUSIONS: Notable registry findings include frequently delayed presentation and a high prevalence of adverse factors such as renal failure and multivessel disease. Positive procedure-related predictors include shorter delay, use of radial access, bivalirudin, drug-eluting stents, and complete revascularization before discharge.
Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Anciano; Angioplastia primaria; Elderly; Infarto de miocardio; Myocardial infarction; Primary angioplasty

Mesh:

Year:  2016        PMID: 27840148     DOI: 10.1016/j.rec.2016.06.012

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  2 in total

Review 1.  From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research.

Authors:  José M de la Torre Hernández; Elazer R Edelman
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2017-08-31

2.  Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction.

Authors:  Daniel Fernández-Bergés; Irene R Degano; Reyes Gonzalez Fernandez; Isaac Subirana; Joan Vila; Manuel Jiménez-Navarro; Silvia Perez-Fernandez; Mercé Roqué; Antoni Bayes-Genis; Francisco Fernandez-Aviles; Antonio Mayorga; Vicente Bertomeu-Gonzalez; Juan Sanchis; Marcos Rodríguez Esteban; Antonio Sanchez-Hidalgo; Esther Sanchez-Insa; Ane Elorriaga; Emad Abu Assi; Alberto Nuñez; Jose Manuel Garcia Ruiz; Pedro Morrondo Valdeolmillos; Daniel Bosch-Portell; Iñaki Lekuona; Andres Carrillo-Lopez; Alberto Zamora; Berta Vega-Hernandez; Javier Alameda Serrano; Catalina Rubert; Luis Ruiz-Valdepeñas; Laura Quintas; Luis Rodríguez-Padial; Jessica Vaquero; Luis Martinez Dolz; Jose A Barrabes; Pedro L Sanchez; Alessandro Sionis; Julio Martí-Almor; Roberto Elosua; Rosa-María Lidon; David Garcia-Dorado; Jaume Marrugat
Journal:  Open Heart       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.